ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PDT Prelude Tst.

80.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Prelude Tst. LSE:PDT London Ordinary Share GB0006992480 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 80.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Prelude Trust Share Discussion Threads

Showing 8451 to 8474 of 8575 messages
Chat Pages: 343  342  341  340  339  338  337  336  335  334  333  332  Older
DateSubjectAuthorDiscuss
20/2/2008
13:00
Ooopa - looks like Tesco dont want ZBD:




Tesco is to extend its use of electronic shelf-edge labelling (ESL) using a system from Swedish vendor Pricer.
Pricer said that Tesco had ordered 400 units for the deli counter of one store and that this has been extended to include an additional 2,750 units for the dry-grocery department in the same store.

Tesco is expecting to create operational efficiencies by using the system, which reduces printing costs and the labour needed to make price changes, according to Pricer.

This is not the first time that Tesco has deployed ESL technology on a small scale. In 2006, Tesco tested a ZBD Displays system at a store in Leicestershire and extended it to another at High Wycombe. The trial included fresh produce and its fish and hot-deli counters (Retail Week December 22, 2006).

Pricer said that Tesco's earlier trials had not achieved all of the promised benefits. However, Tesco said that it is not replacing the labels it has deployed previously.

The grocer has chosen two formats of Pricer's DotMatrix label: a 90mm display for use in dry grocery and 106mm for the deli counter. Both labels will allow Tesco to update price and information wirelessly in real time to the pixel-based displays, which require little power.

The labels will be implemented by Herbert Retail, which has previously supplied the supermarket chain with technology including hand-held computers and mobile printers.

Several continental retailers have used Pricer's systems for a number of years. They include Carrefour – which has deployed more than 11 million electronic labels in its stores – and Casino which has 7 million.

Pricer chief executive Charles Jackson said: "We are pleased by the size of the order. It is a clear signal that Tesco considers Pricer DotMatrix to be a mature, scalable technology for its shelf-edge display."


Sigh

swalker
19/2/2008
21:47
Sciona news - sounds a good move:



"February 19, 2008 09:41 AM Eastern Time PermalinkTo save a permanent link to this news, right-click the dateline (Ctl-click on a Mac) to copy the link.

Evidence Based Nutrition, Inc., First to Offer Sciona MyCellf™ DNA Personalized Genetics Analysis Kit to Chiropractors
Advanced Technology Test Gives Chiropractors & Patients Deeper, More Individualized Knowledge Into Nutritional & Supplement Needs

CHULA VISTA, Calif.--(BUSINESS WIRE)--Evidence Based Nutrition, Inc. (EBN, www.ebnsupplements.com) announced today that it has entered into a strategic alliance with Sciona, Inc. (www.MyCellf.com) to distribute MyCellf™ personalized genetics test kits to chiropractors.

The EBN MyCellf™ Test

This advanced test is performed in the comfort of the individual's home. A cotton swab is used to collect cheek cells from the individual's cheek; much like as seen on television.

After swabbing, the individual answers the lifestyle and health questionnaire about diet and exercise. The swab and completed questionnaire are sent to Sciona for laboratory analysis, where the individual's DNA is analyzed from 27 specific genes. The genetic findings reflect how the individual's genetic makeup metabolizes and utilizes foods and beverages. Combined with the lifestyle answers, the result is valuable insight into the individual's unique nutritional and supplement needs.

A sophisticated, confidential analysis of an individual's DNA profile and Lifestyle Questionnaire is conducted with the proprietary Sciona Genostic Rules Engine™ software. The DNA Nutrition Action Plan makes nutritional and lifestyle recommendations based on an understanding of the individual's unique genetic profile. The Action Plan is a highly accurate assessment based on genetic screening for variations in a specific set of genes that have been proven in numerous studies to respond to nutritional and lifestyle changes.

Chiropractors Provide Individuals with Laboratory Analysis

Approximately two weeks after the analysis, the chiropractor receives a comprehensive report and then meets with the individual to discuss the analysis. The individual learns what, if any, modifications are recommended to his/her lifestyle, nutritional and supplemental regime.

Founder and President of the World Chiropractic Alliance Weighs In

"People are taking all sorts of nutritional supplements. They're also eating fortified-nutrient rich foods – the result is that many people are now ending up on the side of vitamin stacking. Both vitamin deficiency and vitamin overdose are harmful to the body. The EBN MyCellf testing kit eliminates the guess work. Everyone who knows me personally knows that I'm a health fanatic -- so I've decided to have the EBN MyCellf test performed to find out what my DNA discloses," said Terry Rondberg, founder and president of the World Chiropractic Alliance.

Dr. Kurt Donsbach, D.C., N.D., PhD., founder of Evidence Based Nutrition stated, "Proper nutritional balance with chiropractic care enhances the benefits of chiropractic adjustments."

President and CEO of Sciona, Peter Vitulli commented, "The strategic relationship between Sciona and EBN provides entrance into a new and growing market of 60,000-plus chiropractors who perform services on behalf of millions of consumers each year. The use of our Mycellf DNA Kits will assist chiropractors in attracting new business and bringing clients back for continued care and purchase of nutritional supplements – as most of these individuals are seeking optimal health."

The EBN Mycellf Kit is sold directly to licensed chiropractors, nutritionists and healthcare practitioners through the EBN supplement website at www.ebn.supplements.com for resale to their clientele.

Terry Rondberg continued, "It's not CSI, but it's very close. By utilizing advanced technology, it is going to give patients knowledge they can't get anywhere else in the industry." "

rivaldo
13/2/2008
14:34
Thx :o))

Lime Microsystems is launching on an unsuspecting world at Barcelona this week:



"February 05, 2008

Lime Microsystems: First public demonstration of Lime Microsystems' broadband transceiver reference design at MWC; Visit Lime Microsystems at Mobile World Congress, Barcelona, stand 8B91

(M2 PressWIRE Via Thomson Dialog NewsEdge)
RDATE:04022008

Barcelona: The first public demonstration of the world's first MicroTCA
broadband transceiver reference design will be given at Mobile World
Congress by the design's originator, Lime Microsystems. Mobile World
Congress (formerly 3GSM) will be held in Barcelona, February 11 14,
2008.

Demonstrations will be given on the Freescale Semiconductor stand
(stand 8B91 in hall 8) throughout the show.

"Mobile World Congress provides a great opportunity for Lime to
showcase its transceiver technology alongside complementary
technologies such as Freescale's baseband and power amplifier
solutions," comments Dr. Ebrahim Bushehri, CEO of Lime Microsystems.
"Our digitally reconfigurable design supports a variety of network
configurations, bandwidths and data rates, which will cut costs and
inventory for wireless system OEMs and operators. " The reference
design is targeted at small cell base station applications - femtocells
and picocells - and features 6 user-selectable channel bandwidths from
1.5MHz to 14 MHz. The transceiver can be digitally configured to
operate in bands from 350MHz to 4GHz, making it suitable for LTE, WiMAX
and 3G applications. Using a high-level command set, the design can be
configured for half-duplex and full-duplex operation in both frequency
division multiplex (FDM) and time division multiplex (TDM) modes.

Lime Microsystems has design teams in both the UK and Lithuania and has
developed a patent-protected transceiver design that will substantially
reduce the size and cost of next-generation broadband wireless
transceivers.

The company's first semiconductors will be launched in Q1, 2008."

rivaldo
13/2/2008
11:23
No paranoisa, no Polly-anna.
Good luck.

timtom2
13/2/2008
11:02
Sorry TT2, you are completely wrong (paranoid even) :o)) If you care to read recent posts, ralva, others and I (for one) have had a perfectly reasoned and balanced discussion. Hvs can be a little extreme sometimes, but that's his style on all threads, read it and admire it or ignore it. Funnily enough, you are usually as extreme in your posts as hvs is, simply in the opposite direction. Reasoned positivity or negativity rather than outright dismissal is always welcome.

Ralva, I do think M-Spatial may be worth something, especially to the mobile operators, but I agree that funding in this climate will be difficult to say the least! Which is why I left M-Spatial out of my NAV calculations.

Fortunate indeed that a number of companies in the portfolio have arranged decent funding in the last year or so as outlined above.

rivaldo
13/2/2008
10:27
Beware telling it as it is ralva.
Open 2 sided dialogue doesn't go down well on this thread.

timtom2
13/2/2008
09:39
hvs, I think that you are mistaken regarding the prospects for m-spatial, have a look at the extract from the last NAV announcement:

"The reduction in the value of the unquoted portfolio results principally from
provisions taken against portfolio companies, DeNovo, m-spatial and Si-Connect.
The provisions result from those companies having so far failed to make
sufficient progress in developing their businesses, or in finding new investors,merger partners or acquirers."

This is venture capital "speak" for---"we aren't going to put any more money in, nobody else will put any money in and we can't find anyone else mug enough to buy it.
The only place m-spatial is going to is into administration--a shame but unfortunately all too common regarding some of the Prelude investments

ralva
12/2/2008
14:49
Think we have a really big winner here .
hvs
08/2/2008
17:13
Thank you for the posts rivaldo.

Looks like we are heading towards tiur valuation with share price

hvs
08/2/2008
14:57
Hello - something happening?!

Ralva, I completely understand all you say, except...

- as I said earlier, I've been told that management fees are, ahem, under review for the proposals. The obvious point is that if future fees on a run-off are set too high then a run-off would/should be rejected by shareholders.

- the current share price is 76p compared to 121p NAV. If a bidder offered say 100p, that would be a decent premium to the current price (still disappointing, though leaving me well in profit!), but would leave plenty of room for a 30%-40% IRR given the 20% discount to NAV (assuming you trust the valuations).

Kiadis news:



"Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused
biopharmaceutical product development company Kiadis Pharma announced today
that it has successfully finalized its Rhitol(TM) Phase II clinical trial
with the last patient completing its six month treatment cycle. Rhitol(TM)
is evaluated as treatment for patients with extensive chronic Graft versus
Host Disease (GvHD) intolerant or resistant to standard immunosuppressive
treatment.

The current preliminary clinical results demonstrate an excellent
safety profile for Rhitol(TM) and evidence of efficacy in the alleviation
of the symptoms associated with chronic Graft versus Host Disease. After
this clinical study was closed for enrollment mid 2007 Kiadis Pharma
allowed new patients to be treated under a compassionate protocol. The
successful completion of the Phase II clinical trial of Rhitol(TM) paves
the way for a phase III study and Kiadis Pharma is planning to file for a
phase III multi center clinical trial in the USA and Canada within the next
few months.

Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the
positive outcome of this study and the potential shown by Rhitol(TM). This
product would fulfill a significant unmet medical need since patients with
chronic GvHD resistant or intolerant to immunosuppressive drugs have no
other standard treatment option available to them and this disease can
subsequently develop into a life-threatening condition.""

rivaldo
07/2/2008
11:28
Rivaldo I don't dispute your thoughts on valuation, but I would be very suprised if a "secondary buyer" would be prepared to pay anything near these levels.We know from previous comments that the portfolio will not be sold off piecemeal so anyone buying the Prelude portfolio would have to take the bad alongside the good. Secondary buyers would generally look to get an eventual exit producing IRR's for them in the 30% to 40% range. The sort of "knock-out bid" that will result from something like that will almost certainly be rejected by the board. I'm sorry to say that I think you will end up with the existing management team managing the portfolio out for a few more years enabling them to keep their snoughts firmly in the trough of management fees.
Don't be suprised if the proposals contain a clause to "reset" the level of profit share by the manager. Having lost so much money for everyone then this will be an opportunity for them to "start again" at a much reduced NAV level and then take 20% of any "profits" they make from here!

ralva
06/2/2008
16:20
:o))

Just some simple maths. DisplayLink, Oxford ImmMunotech, Xmos, Kiadis, Lime, GreenPeak, Tribold, ZBD and Virtualogix have all had funding round relatively recently. Their valuations are currently £22.2m.

Taking just Phyworks, Polatis and the rump of CPS, their valuations amount to £8.9m.

That's a total of £31.1m, compared to the £25.6m m/cap.

Plus PDT have say £6m cash left.

And the above deliberately (on my part) excludes the likes of Sciona and M-Spatial, which are large investments and which I'm unsure about, though Sciona has also been valued for a funding round pretty recently.

The portfolio may be down-valued due to current economic conditions, but a number of the investees will equally have made progress since the last valuations.

Obviously all opinions are finger-in-the-air stuff. But VC activity is still at a relatively high level. So there is room for optimism as well as caution given PDT's past record.

rivaldo
05/2/2008
16:37
"Siconnect are world leaders in in-home powerline communications technology."
always beware world leaders.

boxwellian
03/2/2008
20:56
£1 - only 20% discount to NAV when further funding rounds may be needed?
Good Luck.

timtom2
03/2/2008
10:35
I reckon of at least £ 1.00 per share. EASY.

With US interest rates going down rapidly , venture capital will be looking at
investing pools of CASH they have.

hvs
01/2/2008
18:07
Rivaldo - what share price do you think would be achieved in a portfolio sell off?
blott
01/2/2008
15:11
I spoke to PDT. FYI:

- the portfolio would be sold as a whole, so there would be no individual company firesale
- on a run-off the opinion was that management fees would be "renegotiated" :o)) I should co-co....

Xmos news:


"Xmos expands team, premises
by David Manners
Tuesday 29 January 2008

Start-up company Xmos Semiconductor has grown its staff numbers to 34 and moved to larger premises in Bristol.

The firm was previously based at the SETsquared University of Bristol incubator.

Xmos' CEO, James Foster, said: "With test silicon back from the fab and our first product expected during Q2 2008 we now need more space to accommodate design, test, applications and marketing personnel. With September's series A funding in place we've been able to move quickly to a dedicated HQ."

The firm has an event-driven, multi-threaded processor engine technology that designers access through a unified C-based software flow. Xmos calls the technology software defined silicon (SDS).

"The SETsquared incubator at the University of Bristol gave us a fantastic platform from which to prove the science of SDS," added Foster."

rivaldo
31/1/2008
11:22
DisplayLink is planning to release a wireless USB adapter, to connect a computer to multiple monitors, in September or October 2008. It will also release wireless USB universal docking stations and monitors at the same time.



DisplayLink have already showcased a wireless display adapter at CES 2008 which enabled PCs or notebooks to connect to multiple displays without the use of wires. It could have the potential to make a big difference at companies where multi-monitor technology was needed, such as financial institutions.

"A display connected using this wireless reference design feels and looks to a user exactly like a wired display," said Hamid Farzaneh, DisplayLink president and chief executive officer. "As evidenced by the proliferation of wireless mice and keyboards, the availability of this technology to bring the same freedom to monitors is just what original equipment manufacturers (OEMs) need to spur explosive growth in this market."

Researchers realised that wireless speeds needed to be fast enough to transfer high resolution as well as DVD quality playback. To do this, ultra-wideband company Alereon provided a worldwide Wi-Media alliance-certified chipset to work with DisplayLink's existing network display technology. It also meant that the resulting products will be compatible with future wireless USB-enabled notebook computers.

"Providing a standards-based design is critical for our OEM partners so they can be assured of compatibility with broadly available laptops and notebooks," said Eric Broockman, chief executive officer of Alereon. "Our partners require the combination of standards-based wireless technology, exceptional throughput and worldwide footprint to achieve mass adoption."

They also said the current wired technology now has support for Windows Vista, with a free software download available from its website.

Previously the technology could only work with older operating systems like Windows XP, but with the new downloadable software all DisplayLink equipment will be able to support the Windows Vista Aero 3D interface. DisplayLink said that this was very important, not only because Windows Vista was being taken up by more businesses but also because the 3D 'glass effect' of Vista would look better in a multiple display environment.

orange1
29/1/2008
13:09
Surprised at the failure of pdt too?

They backed SiConnect for crying out loud.

What else will surprise to the downside before they manage to sell the Trust? If no sale then the holders are trapped and a slave to fortune for a long time?

pinkfish
29/1/2008
09:22
So a company trying to build a business around an old '80s tech idea
(and relatively expensive products based thereof), fails to find
much traction in a 21st century already flooded with cheap WiFi
(and other wireless connectivity) competition.

Is anyone really surprised? No Hmmmmm...

katylied
28/1/2008
22:21
Have been keeping a watching brief on PDT as an x-holder. May be worth buying back in again one day. No offence to ypu personally but I would expect a company CEO to say such things about his company. No CEO worth his salt ever says his company is overvalued or not special or not worth backing etc. etc.

When the companies competitors say what Walker has said about m-spatial then I would sit-up and take notice.

As far as not being profitable yet - when will they be and how long before the money runs out and more dilution is needed or they come to PDT with a begging bowl?

Also, if PDT is to be sold on I would expect the portfolio companies to be rah-rah - they might have been told to be so. They must also be nervous not knowing who the new holder will unltimately be.

At this stage I can't help but take all news on PDT and Portfolio companies with a healthy does of salt.

timtom2
28/1/2008
21:27
m-spatial are not profitable yet but in the words of Andy Walker CEO of m-spatial:

"We are doing fine. This is a really interesting time. First, there is a lot of interest for our solutions from carriers. Of course some are looking for branded search such as Yahoo or Google applications, but others are looking for white label customized solutions such as what we offer.

Second, looking at the consumers, when we started this business nobody knew you could do local search with a mobile phone, now it is really starting to change. There is more and more consumer awareness. Also I think things like the iPhone are really shaking up the market in providing real data centric devices to consumers.

Third, I think also our experience with ad-funded models is very interesting for navigation providers that will look more and more into that direction."

For the full interview, see:

orange1
28/1/2008
07:56
This is a bad time to be selling a portfolio of holdings, particularly by a management with a poor track record. I cannot see a simple solution to the problem they have created.
jtjh
28/1/2008
07:55
Time for a new thread name?
timtom2
Chat Pages: 343  342  341  340  339  338  337  336  335  334  333  332  Older

Your Recent History

Delayed Upgrade Clock